The KBTBD2 Knockout HAP1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal cell population derived from the near-haploid HAP1 cell line, engineered for targeted disruption of the KBTBD2 gene. This tool provides a loss-of-function model for investigating the role of KBTBD2 as a substrate adaptor within the Cullin?3?CRBX1 E3 ubiquitin ligase complex. The polyclonal format ensures a heterogeneous mixture of knockout alleles, enabling robust functional genomics studies while mitigating clonal artifacts. By abolishing KBTBD2 function, researchers can dissect its contribution to ubiquitin-mediated proteasomal degradation pathways, particularly in the context of insulin signaling regulation.
HAP1 cells represent a human chronic myeloid leukemia-derived line with a near-haploid karyotype, originally generated from the KBM-7 cell line. This haploid genetic background simplifies CRISPR/Cas9-mediated knockout strategies by requiring disruption of only a single allele, thereby facilitating generation of loss-of-function models even for essential genes. The cells?? stable proliferation and well-characterized signaling networks make them a versatile platform for systematic functional genomic screens and pathway dissection. Their human origin ensures physiological relevance for studying metabolic and oncogenic signaling pathways, while compatibility with diverse molecular and cellular assays enhances experimental flexibility.
KBTBD2 encodes an adaptor protein that recruits substrates to the Cullin?3 (CUL3)?CRBX1 E3 ubiquitin ligase complex for ubiquitination and subsequent proteasomal degradation. Among its targets, KBTBD2 promotes the degradation of insulin receptor substrate 1 (IRS1), a key node in the insulin signaling cascade. By regulating IRS1 stability, KBTBD2 acts as a negative modulator of insulin?stimulated PI3K?Akt signaling, attenuating downstream metabolic responses. The protein interacts directly with CUL3, RBX1, and ubiquitin, and its activity is sensitive to cellular metabolic status, though upstream regulators remain undefined. Disruption of KBTBD2 thus relieves suppression of IRS1, potentially enhancing insulin sensitivity and altering glucose homeostasis.
In the HAP1 background, the near-haploid genome permits efficient disruption of the single KBTBD2 allele, yielding a uniform loss-of-function phenotype ideal for linking genotype to phenotype. This system is particularly valuable for exploring mechanisms of insulin resistance and type 2 diabetes, where aberrant KBTBD2 activity may contribute to metabolic dysregulation. The combination of haploid genetics and a human leukemic background also provides a platform for studying cross?talk between metabolic and oncogenic signaling, as insulin?PI3K?Akt pathways are frequently co?opted in cancer.
Typical applications of these polyclonal knockout cells include insulin stimulation assays to measure IRS1 protein levels and AKT phosphorylation by western blotting, as well as ubiquitination assays to assess substrate modification following proteasome inhibitor treatment. RT?qPCR can profile metabolic gene expression, while flow cytometry permits analysis of proliferation or apoptosis under varied nutrient conditions. Researchers can also integrate the cells into pooled CRISPR screens to validate drug targets or optimize screening workflows. This product is suitable for functional genomics, metabolic disease research, and insulin signaling studies. For additional details or support, please contact Ascent Research.
